The TBSGC focuses on perturbing cellular functions and studying their effects by identifying compounds to bind and inhibit new target proteins. Early hits aid crystallization and validate target inhibition in cells, investigating synergistic activity with other drugs. These hits, developed through SAR and medicinal chemistry, progress into potent inhibitors evaluated in TB animal models.

 

This core is pivotal, supporting small molecule inhibitor activities related to project targets. With extensive involvement in hit identification and assessment, the P01 grant and TBDA (TB Drug Accelerator) Program, the project aims to deliver inhibitors with known mechanisms, attractive activity, and favorable PK data to pharma partners for subsequent drug development.